Strategic partnership Omeros recently secured a deal with Novo Nordisk valued up to $2.1B for zaltenibart, signaling strong interest from large pharma and a potential for co-development, manufacturing, or co-commercialization opportunities with similar partners in inflammation, coagulopathies, or CNS disorders.

Pipeline expansion Active development of OMS527 for cocaine use disorder and ongoing TA-TMA program presentations indicate a broad, multi-indication pipeline. This creates cross-sell potential to pull in collaboration discussions around companion diagnostics, specialty hematology, and kidney disease markets.

Commercial leadership Past success launching Yartemlea for hematologic and immune-mediated conditions demonstrates Omeros’ commercial capabilities in rare diseases. This suggests advisory or contract manufacturing/market access partnerships for new launches and orphan indications.

Executive transition Recent leadership changes in Chief Commercial and Chief Medical roles may open opportunities for interim advisory roles, consulting partnerships, or targeted BD discussions around strategic realignment, risk mitigation, and accelerated go-to-market plans.

Financial runway Strong funding position with near $1B in funding and reported revenues in the $100M–$250M range supports exploratory partnerships, upfront collaboration deals, and milestone-based arrangements with larger biotechs seeking rapid expansion without immediate R&D capital strain.